作者
Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto
发表日期
2021/3/1
期刊
JAMA oncology
卷号
7
期号
3
页码范围
386-394
出版商
American Medical Association
简介
Importance
Although treatment with first-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies in patients withEGFR-mutated lung adenocarcinoma, recent single-arm studies have suggested that osimertinib plus antiangiogenic inhibitor might not work synergistically.
Objective
To explore the efficacy and safety of osimertinib plus bevacizumab compared with osimertinib alone in patients with lung adenocarcinoma withEGFRT790M mutation.
Design, Setting, and Participants
Patients with advanced lung adenocarcinoma that progressed with prior EGFR-TKI treatment (other than third-generation TKI) and acquiredEGFR T790M mutation were enrolled. This study comprises a lead-in part with 6 patients and a subsequent phase 2 part. In phase 2, patients were randomized to osimertinib plus bevacizumab or osimertinib alone in a 1 …
学术搜索中的文章
H Akamatsu, Y Toi, H Hayashi, D Fujimoto… - JAMA oncology, 2021